Tumour angiogenesis is prevented by mTOR inhibitors through two mechanisms: i) decreased synthesis and release of angiogenic growth factors (especially VEGF) from the cancer cells and ii) blocked growth by the reduction of vascular cell survival. Here, MTOR is linked to neoplasm.